Clinical Trial Update: Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating surufatinib plus anti-PD-1/PD-L1 as maintenance therapy in extensive-stage small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Anti-PD-1/PD-L1 agent
• Surufatinib (Surufatinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Extensive-Stage Small Cell Lung Cancer | Phase 2 | Status: COMPLETED